Literature DB >> 7872750

Guanylhydrazones in therapy of Pneumocystis carinii pneumonia in immunosuppressed rats.

P D Walzer1, J Foy, J Runck, P Steele, M White, R S Klein, B A Otter, R J Sundberg.   

Abstract

Guanylhydrazones are cationic heteroaromatic drugs similar to the diamidines which are effective in the treatment of African trypanosomiasis and pneumocystosis. On the basis of their antitrypanosomal activity, different guanylhydrazones were selected for evaluation in a rat model of Pneumocystis carinii pneumonia. The most active compounds were the 2-(4'-formylphenyl)-1-methylimidazo-[1,2-a] pyridinium guanylhydrazones which, at a dose of 2 mg/kg/day, were about as effective as trimethoprim-sulfamethoxazole at a dose of 50 mg of trimethoprim per kg/day plus 250 mg of sulfamethoxazole per kg/day. The anti-P. carinii activity of these guanylhydrazone derivatives was found with parenteral but not with oral administration. The 1,3-arylene diketone bis(guanylhydrazones) were generally ineffective, although a triacetyl derivative showed some anti-P. carinii activity. Nitroimidazole guanylhydrazone derivatives were also ineffective. Attempts to improve the therapeutic efficacy of the different guanylhydrazones were limited by problems of toxicity. We conclude that some guanylhydrazone derivatives are potent anti-P. carinii drugs and that further studies should be pursued to develop safer compounds and investigate structure-activity relationships.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7872750      PMCID: PMC188244          DOI: 10.1128/AAC.38.11.2572

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  28 in total

Review 1.  Prevention and treatment of pneumocystis pneumonia.

Authors:  H Masur
Journal:  N Engl J Med       Date:  1992-12-24       Impact factor: 91.245

2.  Petite mutagenesis in Saccharomyces cerevisiae by a series of bis-cationic trypanocidal drugs.

Authors:  L R Ferguson; R J Sundberg
Journal:  Antimicrob Agents Chemother       Date:  1991-11       Impact factor: 5.191

3.  Inhibition of topoisomerases from Pneumocystis carinii by aromatic dicationic molecules.

Authors:  C C Dykstra; R R Tidwell
Journal:  J Protozool       Date:  1991 Nov-Dec

4.  Analogues of 1,5-bis(4-amidinophenoxy)pentane (pentamidine) in the treatment of experimental Pneumocystis carinii pneumonia.

Authors:  R R Tidwell; S K Jones; J D Geratz; K A Ohemeng; M Cory; J E Hall
Journal:  J Med Chem       Date:  1990-04       Impact factor: 7.446

5.  Topical melarsoprol for trypanosomiasis.

Authors:  F W Jennings; J M Atouguia; M Murray
Journal:  Lancet       Date:  1993-05-22       Impact factor: 79.321

6.  Selective cleavage of kinetoplast DNA minicircles promoted by antitrypanosomal drugs.

Authors:  T A Shapiro; P T Englund
Journal:  Proc Natl Acad Sci U S A       Date:  1990-02       Impact factor: 11.205

7.  Deferoxamine and eflornithine (DL-alpha-difluoromethylornithine) in a rat model of Pneumocystis carinii pneumonia.

Authors:  A B Clarkson; M Sarić; R W Grady
Journal:  Antimicrob Agents Chemother       Date:  1990-09       Impact factor: 5.191

8.  Structure and DNA binding activity of analogues of 1,5-bis(4-amidinophenoxy)pentane (pentamidine)

Authors:  M Cory; R R Tidwell; T A Fairley
Journal:  J Med Chem       Date:  1992-02-07       Impact factor: 7.446

Review 9.  Treatment of experimental pneumocystosis: review of 7 years of experience and development of a new system for classifying antimicrobial drugs.

Authors:  P D Walzer; J Foy; P Steele; M White
Journal:  Antimicrob Agents Chemother       Date:  1992-09       Impact factor: 5.191

10.  Structure, DNA minor groove binding, and base pair specificity of alkyl- and aryl-linked bis(amidinobenzimidazoles) and bis(amidinoindoles).

Authors:  T A Fairley; R R Tidwell; I Donkor; N A Naiman; K A Ohemeng; R J Lombardy; J A Bentley; M Cory
Journal:  J Med Chem       Date:  1993-06-11       Impact factor: 7.446

View more
  6 in total

Review 1.  Treatment of infection due to Pneumocystis carinii.

Authors:  J A Fishman
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

2.  QacA multidrug efflux pump from Staphylococcus aureus: comparative analysis of resistance to diamidines, biguanidines, and guanylhydrazones.

Authors:  B A Mitchell; M H Brown; R A Skurray
Journal:  Antimicrob Agents Chemother       Date:  1998-02       Impact factor: 5.191

3.  In vitro selection and in vivo efficacy of piperazine- and alkanediamide-linked bisbenzamidines against Pneumocystis pneumonia in mice.

Authors:  Melanie T Cushion; Peter D Walzer; Alan Ashbaugh; Sandra Rebholz; Ronald Brubaker; Jean Jacques Vanden Eynde; Annie Mayence; Tien L Huang
Journal:  Antimicrob Agents Chemother       Date:  2006-07       Impact factor: 5.191

4.  Clinically used antimicrobial drugs against experimental pneumocystosis, singly and in combination: analysis of drug interactions and efficacies.

Authors:  P D Walzer; J Runck; S Orr; J Foy; P Steele; M White
Journal:  Antimicrob Agents Chemother       Date:  1997-02       Impact factor: 5.191

5.  Immunodeficient and immunosuppressed mice as models to test anti-Pneumocystis carinii drugs.

Authors:  P D Walzer; J Runck; P Steele; M White; M J Linke; C L Sidman
Journal:  Antimicrob Agents Chemother       Date:  1997-02       Impact factor: 5.191

6.  In vitro and in vivo effects of quinupristin-dalfopristin against Pneumocystis carinii.

Authors:  P D Walzer; A Ashbaugh; M Collins; M T Cushion
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.